Literature DB >> 11346677

Docetaxel: overview of an active drug for breast cancer.

J Crown1.   

Abstract

Docetaxel and paclitaxel differ in their precise molecular targets and pharmacokinetics. Docetaxel is more avidly taken up by tumor cell lines than paclitaxel, and its efflux is slower. Comparative cytotoxicity data suggest greater potency. These factors may help explain the clinical differences that have been observed between the taxanes in patients with breast cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11346677     DOI： 10.1634/theoncologist.6-suppl_3-1

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  6 in total

1.  A phase I study of flavopiridol and docetaxel.

Authors:  Basil F El-Rayes; Shirish Gadgeel; Ralph Parchment; Patricia Lorusso; Philip A Philip
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

2.  Zebrafish phenotypic screen identifies novel Notch antagonists.

Authors:  Vithya Velaithan; Kazuhide Shaun Okuda; Mei Fong Ng; Norazwana Samat; Sze Wei Leong; Siti Munirah Mohd Faudzi; Faridah Abas; Khozirah Shaari; Sok Ching Cheong; Pei Jean Tan; Vyomesh Patel
Journal:  Invest New Drugs       Date:  2017-01-05       Impact factor: 3.850

3.  Docetaxel as single-agent treatment in elderly patients with advanced breast cancer.

Authors:  I Lorenzo; M Constenla; P Palacios; F R García-Arroyo; I Fernández; B Campos; L Salgado; N Carrete
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

4.  The effects of taxanes, vorinostat and doxorubicin on growth and proliferation of Echinococcus multilocularis metacestodes assessed with magnetic resonance imaging and simultaneous positron emission tomography.

Authors:  Xiangsheng Huang; Stefan Wiehr; Anna-Maria Wild; Patrick Voßberg; Wolfgang Hoffmann; Beate Grüner; Carsten Köhler; Peter T Soboslay
Journal:  Oncotarget       Date:  2018-01-10

5.  Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Authors:  Kenichi Inoue; Jun Ninomiya; Tsuyoshi Saito; Katsuhiko Okubo; Takashi Nakakuma; Hirofumi Yamada; Kei Kimizuka; Tohru Higuchi
Journal:  Invest New Drugs       Date:  2019-03-08       Impact factor: 3.850

6.  Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines.

Authors:  Natalia Vargas-Rondón; Erika Pérez-Mora; Victoria E Villegas; Milena Rondón-Lagos
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.